WashingtonVotes.org
your lawmakers' votes at your fingertips
your lawmakers' votes at your fingertips
Legislation watch
2018 House Bill 2565: Concerning drug and gene therapy payment for medicaid managed care organizations
Introduced by Rep. Joe Schmick (Adams) (R) on January 10, 2018
Referred to the House Health Care & Wellness Committee on January 10, 2018
Substitute offered in the House on February 2, 2018
Adds members from each of the Medicaid managed care organizations to the Health Care Authority's (Authority's) Pharmacy and Therapeutics Committee.
Referred to the House Rules Committee on February 6, 2018
Amendment offered by Rep. Joe Schmick (Adams) (R) on February 9, 2018
Changes the term "gene therapies" to "innovative
therapies".
The amendment passed by voice vote in the House on February 9, 2018
Amendment offered by Rep. Vandana Slatter (Kirkland) (D) on February 9, 2018
Requires the Drug Utilization Review (DUR) Board, when
considering new drugs and innovative therapies, to consider the 27
safety, efficacy, and cost-effectiveness in comparison to equally
effective, more conservative, or substantially less costly courses of treatment that are available or suitable.
The amendment passed by voice vote in the House on February 9, 2018
Received in the Senate on February 13, 2018
Referred to the Senate Health & Long-Term Care Committee on February 13, 2018